With the increased expression of PD-L1, MHC-I, and CRT in tumor cells, cGAS/STING overexpression changes tumor immunogenicity and improves anti-PD-L1 treatments in in vitro and in vivo mice models [95,197]. The gene discussed is STING1; the disease is neoplasm.